Home / Business and Economy / Lantheus Weighs Sale Amidst Curium Acquisition Offer
Lantheus Weighs Sale Amidst Curium Acquisition Offer
6 Jun
Summary
- Lantheus is considering a sale following a takeover bid from Curium.
- Curium, a rival radiopharmaceutical company, made the acquisition offer.
- Lantheus primarily generates revenue from its product PYLARIFY.
Lantheus Holdings Inc. is currently evaluating a potential sale, prompted by a takeover offer from its competitor, Curium. This development places Lantheus at a pivotal moment within the radiopharmaceutical industry.
Curium, known for its production of radioactive tracers essential for nuclear medicine, has submitted an acquisition proposal. The offer from Curium is reportedly a significant one, indicating a strong interest in consolidating market presence.
Lantheus derives a substantial portion of its revenue from the sale of its product, PYLARIFY. The company's strategic decision to consider a sale reflects the dynamic nature of the pharmaceutical sector and potential shifts in market leadership.
